RxDoctor Payments Data

Heather Cherney

Nurse Practitioner · Reedsburg, WINPI 1326608134

Payments from drug & device makers

$733in general payments, 2019–2025

Across 18 payments — averaging $40.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$161
  • E.r. Squibb & Sons, L.L.C.$157
  • Bridgebio Pharma, Inc.$131
  • Medtronic$113
  • Novo Nordisk$82
  • Amgen$21
  • plus $67 from 4 others

What the payments were for

  • Food & beverage$63386%
  • Education$10014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$733 in reported general payments places this provider in the 85th percentile of 3,478 nurse practitioner providers in Wisconsin.

See all nurse practitioner providers in Wisconsin

Medicare billing

Part B allowed, 2024
$15,506
Medicare patients
18
Services billed
1,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban163$108,136
EliquisApixaban91$107,947
JardianceEmpagliflozin107$96,384
FarxigaDapagliflozin Propanediol55$51,102
EntrestoSacubitril/Valsartan41$32,186
Repatha SyringeEvolocumab13$14,978
Metoprolol Succinate219$2,736
Ezetimibe57$1,472
Atorvastatin Calcium160$1,143
Flecainide Acetate43$977
Diltiazem 24hr Er (Cd)Diltiazem Hcl36$660
Rosuvastatin Calcium127$649
Furosemide141$620
Isosorbide Mononitrate ErIsosorbide Mononitrate31$584
Carvedilol92$471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$20$108,136163 claims
AstraZenecaFarxiga$161$51,10255 claims
NovartisEntresto$17$32,18641 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,478 nurse practitioner providers in Wisconsin.

Other nurse practitioner in Reedsburg

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →